Prognostic versus predictive value of biomarkers in oncology

Abstract Numerous options are currently available for tumour typing. This has raised intense interest in the elucidation of prognostic and predictive markers. A prognostic biomarker provides information about the patients overall cancer outcome, regardless of therapy, whilst a predictive biomarker g...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2008-05, Vol.44 (7), p.946-953
Main Authors: Oldenhuis, C.N.A.M, Oosting, S.F, Gietema, J.A, de Vries, E.G.E
Format: Article
Language:English
Subjects:
Apoptosis - physiology
Biological and medical sciences
Biomarker
Biomarkers, Tumor - metabolism
Hematology, Oncology and Palliative Medicine
Humans
Medical sciences
Neoplasm Recurrence, Local - diagnosis
Neoplasms - diagnosis
Pharmacology. Drug treatments
Predictive factor
Predictive Value of Tests
Prognosis
Prognostic factor
Therapy
Tumor Necrosis Factor-alpha - metabolism
Tumors
Vascular Endothelial Growth Factor A - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Numerous options are currently available for tumour typing. This has raised intense interest in the elucidation of prognostic and predictive markers. A prognostic biomarker provides information about the patients overall cancer outcome, regardless of therapy, whilst a predictive biomarker gives information about the effect of a therapeutic intervention. A predictive biomarker can be a target for therapy. Amongst the genes that have proven to be of relevance are well-known markers such as ER, PR and HER2/neu in breast cancer, BCR–ABL fusion protein in chronic myeloid leukaemia, c-KIT mutations in GIST tumours and EGFR1 mutations in NSCLC. Several reasons for the difficult elucidation of new markers will be addressed including the involvement of cellular pathways in tumour biology instead of single genes and interference in disease outcome as a result of anticancer therapies. Future perspectives for the development of prognostic and predictive markers will be given.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2008.03.006